Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Julphar
Cipla
Express Scripts
Medtronic
QuintilesIMS
McKinsey
Fuji
Citi

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CARVEDILOL

« Back to Dashboard

Clinical Trials for Carvedilol

Trial ID Title Status Sponsor Phase Summary
NCT00000294 Effects of Carvedilol on Cocaine Use in Humans - 11 Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 The purpose of this study is to examine carvedilol effects in response to cocaine.
NCT00000294 Effects of Carvedilol on Cocaine Use in Humans - 11 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to examine carvedilol effects in response to cocaine.
NCT00004854 The Safety and Efficacy of Adjunct Carvedilol in Children With Moderate Heart Failure Completed National Center for Research Resources (NCRR) Phase 1 We would like to see if using Carvedilol in adjunct with Ace inhibitors will increase ejection fraction of the heart under echo. All interpretation of data will be sent to Boston Children's Hospital to be reviewed, which is the primary research center in this study. There are 5 hospitals participating in this study. The population targeted are children with moderate heart failure and must be on Ace inhibitors at the time of enrollment. Our outcome after placing them on Carvedilol is to change their ejection fraction on echo. The patients will be seen every 1-2 weeks, while we will titrate their medication to a maintenance dose. Secondary outcome is to increase quality of life, exercise tolerance and decrease their symptom scores as noted on their questionnaires.
NCT00052026 Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure Completed University of Utah Phase 3 The purpose of this study is to determine whether a new medicine, called carvedilol, improves symptoms and heart function in children who have congestive heart failure (diminished function of their heart muscle that pumps blood to the body). To accomplish this, we will give carvedilol to some patients who have diminished heart function and congestive heart failure and see whether symptoms and heart function are better at the end of an 8 month period in those who received carvedilol compared to the other patients who did not receive carvedilol. We will be testing 2 different doses of carvedilol compared to no additional medicine.
NCT00052026 Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure Completed Shaddy, Robert, M.D. Phase 3 The purpose of this study is to determine whether a new medicine, called carvedilol, improves symptoms and heart function in children who have congestive heart failure (diminished function of their heart muscle that pumps blood to the body). To accomplish this, we will give carvedilol to some patients who have diminished heart function and congestive heart failure and see whether symptoms and heart function are better at the end of an 8 month period in those who received carvedilol compared to the other patients who did not receive carvedilol. We will be testing 2 different doses of carvedilol compared to no additional medicine.
NCT00060918 Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension Completed GlaxoSmithKline Phase 4 To evaluate the effects of two different antihypertensive medications in the drug class of beta-blockers on control of glucose in Type II diabetic patients with high blood pressure.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Carvedilol

Condition Name

Condition Name for Carvedilol
Intervention Trials
Hypertension 22
Heart Failure 16
Healthy 11
Cirrhosis 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Carvedilol
Intervention Trials
Hypertension 36
Heart Failure 32
Hypertension, Portal 9
Liver Cirrhosis 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Carvedilol

Trials by Country

Trials by Country for Carvedilol
Location Trials
United States 377
Japan 36
China 20
Korea, Republic of 16
Canada 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Carvedilol
Location Trials
New York 20
Texas 18
California 15
Illinois 14
Florida 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Carvedilol

Clinical Trial Phase

Clinical Trial Phase for Carvedilol
Clinical Trial Phase Trials
Phase 4 47
Phase 3 27
Phase 2/Phase 3 1
[disabled in preview] 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Carvedilol
Clinical Trial Phase Trials
Completed 69
Recruiting 30
Unknown status 16
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Carvedilol

Sponsor Name

Sponsor Name for Carvedilol
Sponsor Trials
GlaxoSmithKline 23
Institute of Liver and Biliary Sciences, India 6
National Institute on Drug Abuse (NIDA) 5
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Carvedilol
Sponsor Trials
Other 148
Industry 55
NIH 16
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Dow
Colorcon
Mallinckrodt
US Army
Federal Trade Commission
McKinsey
US Department of Justice
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.